Screener
ArriVent BioPharma, Inc. AVBP Other operating expenses
Other operating expenses at other companies
Other financials
Where this comes from
Reported directly by ArriVent BioPharma, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingExpenses.
The source filing: ArriVent BioPharma, Inc.’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 4:08 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-058650
| Line item | Three Months Ended / March 31, 2026 | Three Months Ended / March 31, 2025 |
|---|---|---|
| Operating expenses: | ||
| Research and development | $37,617 | $61,289 |
| General and administrative | 8,494 | 5,483 |
| Total operating expenses | 46,111 | 66,772 |
| Operating loss | (46,111) | (66,772) |
| Interest and investment income | 2,791 | 2,385 |
| Net loss | (43,320) | (64,387) |
| Unrealized gain (loss) on marketable securities | (284) | 194 |
Item 1. Condensed Financial Statements (Unaudited):
FAQ
- What is ArriVent BioPharma, Inc.'s other operating expenses?
- ArriVent BioPharma, Inc. (AVBP) reported other operating expenses of $46.11M in Q1 2026.
- How has ArriVent BioPharma, Inc.'s other operating expenses changed year-over-year?
- ArriVent BioPharma, Inc.'s other operating expenses decreased by 30.9% year-over-year, from $66.77M to $46.11M.
- What is the long-term trend for ArriVent BioPharma, Inc.'s other operating expenses?
- Over 2 years (2023 to 2025), ArriVent BioPharma, Inc.'s other operating expenses has grown at a 54.3% compound annual growth rate (CAGR), from $74.59M to $177.53M.
- What does other operating expenses mean?
- Residual operating expenses not classified into specific categories, serving as a catch-all for miscellaneous operating costs.
Ask your AI about ArriVent BioPharma, Inc.'s other operating expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude